Insilico Nominates AI-Designed ISM9077, Potential First-in-Class Y Inhibitor, as Preclinical Candidate
Insilico Medicine Nominates AI-Designed ISM9077 as Preclinical Candidate for Ocular Disease and Aging-Related Inflammation Insilico Medicine has nominated ISM9077, an ...
